Stay updated with breaking news from Tarun saluja. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Efforts are underway to consider sex differences in drug development by increasing woman’s participation in clinical trials, but the lack of regulatory guidelines remains a barrier to taking gender diversity into account, experts say. The COVID-19 pandemic and South Korea’s vaccination programs have shed light on how a disease and its treatment can affect men and women differently. According to the Korea . ....
HAPPY BIRTHDAY AKSHAYE KHANNA: From his award-winning role as Siddarth Sinha in Dil Chahta Hai to bringing alive the character of Harilal Gandhi in Gandhi: My Father, Akshaye Khanna has always stunned the audience with his versatile characters. To remark on his 48th birthday, here are a few of his movies that you can watch ....
Vi-DT typhoid conjugate vaccine met primary endpoints in phase III study Vi-DT typhoid conjugate vaccine, developed jointly by the International Vaccine Institute (IVI) and SK bioscience, has met the primary endpoints in a phase III study in Nepal. The primary endpoints were based on immune non-inferiority with the WHO-prequalified typhoid conjugate vaccine, Typbar-TCV®, in terms of serconversion rate, which confirms the new candidate TCV induces an immune response that is not inferior to Typbar-TCV®. Three different production lots of vaccine were administered in the clinical trial, and the analysis also shows that these different batches were similar in immunogenicity. Lot-to-lot consistency in manufacturing is an important requirement to ensure the quality of Vi-DT. ....
IVI-SK s new typhoid conjugate vaccine meets primary endpoints in phase III study in Nepal December 17, 2020 - SEOUL, South Korea - Vi-DT typhoid conjugate vaccine, developed jointly by the International Vaccine Institute (IVI) and SK bioscience, has met the primary endpoints in a phase III study in Nepal. The primary endpoints were based on immune non-inferiority with the WHO-prequalified typhoid conjugate vaccine, Typbar-TCV®, in terms of serconversion rate, which confirms the new candidate TCV induces an immune response that is not inferior to Typbar-TCV®. Three different production lots of vaccine were administered in the clinical trial, and the analysis also shows that these different batches were similar in immunogenicity. Lot-to-lot consistency in manufacturing is an important requirement to ensure the quality of Vi-DT. ....